Bispecific T-cell engager (BiTE)

Bispecific T-cell engager Overview

Bispecific T-cell engagers (BiTEs) are engineered antibody-derived fusion proteins designed to direct the body's immune response against cancer (and sometimes autoreactive) cells by physically linking T cells to target cells. One part of the BiTE binds to CD3 on T cells, while the other binds to a tumor-associated antigen on the surface of the target cell. This dual specificity brings T cells into close contact with the malignant cell, resulting in T cell activation and target cell lysis[1][2][3][4][5][7][8]. The best-known approved agents in this class, such as blinatumomab, are used primarily for cancer therapy, particularly hematologic malignancies, but other BiTEs are advancing for solid tumors and autoimmune indications. Importantly, "T-cell engager" is not a single molecular target or receptor; it represents an entire drug modality or class of therapeutic molecules, not a specific protein or gene. Therefore, it is not considered a therapeutic target in itself, but rather a type of biologic drug engineered to redirect immune effector cells for therapeutic benefit.

Mechanism of Action

Redirects T cells to target and kill cells expressing specific antigens (typically cancer cells) by simultaneously binding CD3 on T cells and a tumor-associated antigen on the target cell. Activates T cells through CD3 to mediate cytotoxicity against targeted cells.

Biological Functions

Safety Considerations

Interacting Drugs

Associated Biomarkers